News
Taltz delivers more cumulative days with completely clear skin for adults with psoriasis compared to seven other biologics in novel network meta-analysis.- Eli Lilly
Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's Taltz (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis .
In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.
Taltz Provided Patients with Longest-Lasting Complete Skin Clearance over a One-Year Period : In the network meta-analysis to assess the cumulative clinical benefits of biologics in psoriasis, using PASI 100 to measure the early and sustained effect of biologic medications approved for psoriasis over one year, Taltz offered patients with psoriasis the greatest number of cumulative days of completely clear skin compared to adalimumab, brodalumab, etanercept, guselkumab, risankizumab, secukinumab and ustekinumab. In this analysis, Taltz showed one to 18 more cumulative weeks of completely clear skin over one year compared to these seven other biologics.
Taltz provided patients with a total of 159 cumulative days (95% credible interval, 147.4-170.0 days), or 23 weeks of completely clear skin (PASI 100), which translates into a patient having completely clear skin for approximately 44% of the year compared to: risankizumab (152 days [141.6-162.0 days], or 22 weeks and 42% of the year); brodalumab (138 days [119.0-157.2 days], 20 weeks and 38% of the year); guselkumab (131 days, [120.8-141.6 days], 19 weeks and 36% of the year); secukinumab (119 days [111.7-127.0 days], or 17 weeks and 33% of the year); ustekinumab (74 days [63.3-84.4 days], or 11 weeks and 20% of the year), adalimumab (67 days [55.7-77.9 days], or 10 weeks and 18% of the year) and etanercept (32 days [23.7-39.7 days], or 5 weeks and 9% of the year).
Taltz Helped Patients Stay on Prescribed Treatment, and to Avoid Additional Psoriasis Therapy Significantly Longer, Compared to Secukinumab, Ustekinumab, Adalimumab and Etanercept : People with psoriasis taking Taltz achieved greater success taking medication as prescribed (adherence) and staying on medication for the prescribed duration (persistence), without needing additional medications (monotherapy), compared to those taking secukinumab, ustekinumab, adalimumab and etanercept up to three years. Patients on Taltz stayed on treatment an observed median of nearly 22 weeks longer vs. all other biologics pooled (414 vs. 259 days, [59 vs. 37 weeks], p<0.001) and approximately 11 to 34 weeks longer vs. individual treatments: secukinumab (335 days [48 weeks]), adalimumab (301 days [43 weeks]), etanercept (181 days [26 weeks]) and ustekinumab (176 days [25 weeks]). compared with the pooled set of other biologics where patients stayed on prescription for less than half of the year (45.7%), patients on taltz took treatment as prescribed for over half of the year (53.2%), as measured by proportion of days covered (pdc) by prescribed treatment (p><0.001). patients taking taltz also experienced more time (52.7% of the year) on monotherapy compared to the pooled set of other biologics (44.8% of the year) (p><0.001). patients on taltz took treatment as prescribed nearly eight weeks more than guselkumab, despite more frequent dosing : compared to guselkumab, patients with psoriasis on taltz adhered to treatment for nearly eight weeks more time (taltz: median of 272 days or 39 weeks [pdc="0.75];" guselkumab: 219 days or 31 weeks [pdc="0.60]," p="0.001)" and had approximately six weeks more time on monotherapy (taltz: median of 247 days or 35 weeks [pdc="0.68];" guselkumab: 202 days or 29 weeks [pdc="0.55]," p="0.002)" over one year. among those patients who required additional psoriasis therapies, the need for systemic medication was similar for patients taking taltz or guselkumab over the year. patients on taltz with prior biologic use were more likely to continue treatment as prescribed compared to secukinumab : among participants who had previously used a biologic, patients with psoriasis treated with taltz were more likely to be "highly adherent," which was measured by more than 80% of days where they took treatments as prescribed (taltz: 42.0% vs. secukinumab: 35.0%, p="0.019)." taltz was associated with 25% lower risk of switching treatments, 20% lower risk of stopping treatment before the end of the prescribed duration (non-persistence), 19% lower risk of discontinuing treatment, and 36% higher odds of taking treatment as prescribed (adherence) than secukinumab. "these new data reveal real-world evidence showing that patients with psoriasis who were treated with ixekizumab stay on treatment longer compared to several other biologics, regardless of past biologic experience," said andrew blauvelt, m.d., m.b.a., a board-certified dermatologist, president of oregon medical research center, and lead author of these analyses. "the ability to stay on a biologic over time correlates with treatment success, whereas switching biologic therapies in practice is associated with more time, healthcare costs and patient dissatisfaction. these data demonstrate high treatment persistence with ixekizumab, and thus provide important data for dermatologists to consider when choosing a biologic therapy for their psoriasis patients.">0.001).>0.001).>0.001)>
Condition: Psoriasis
Type: drug